Navigation Links
Rigel Will Resume Responsibility for Fostamatinib Program
Date:6/3/2013

SOUTH SAN FRANCISCO, Calif., June 4, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and AstraZeneca AB (AZ) today announced the topline results from OSKIRA-2 and OSKIRA-3, the remaining pivotal Phase 3 clinical trials investigating fostamatinib, the first oral spleen tyrosine kinase (SYK) inhibitor in development for rheumatoid arthritis (RA). 

In the OSKIRA-2 study of patients inadequately responding to disease modifying anti-rheumatic drugs (DMARDs), fostamatinib in combination with DMARDs showed statistically significant improvements in ACR20 response rates at 24 weeks in both the 100 mg twice daily (bid) group and the group receiving 100 mg bid for four weeks followed by 150 mg once daily (qd) compared to placebo.

In the OSKIRA-3 study of patients inadequately responding to methotrexate (MTX) and a single TNF-alpha antagonist, fostamatinib in combination with MTX showed statistically significant improvements in ACR20 response rates at 24 weeks in the 100 mg bid group, but not in the group given 100 mg bid for four weeks followed by 150 mg qd compared to placebo.

Fostamatinib ACR20 Scores  OSKIRA1

OSKIRA2

OSKIRA3100 mg bid

49%, p<0.001

39.6%, p<0.001

36.2%, p=0.004100 mg bid/150 mg qd

44%, p=0.006

39.6%, p<0.001

27.8%, p=0.168Placebo

34%

24.5%

21.1%Fostamatinib continues to be well tolerated by patients. The safety findings in both the OSKIRA-2 and OSKIRA-3 studies were generally consistent with those observed in the prior OSKIRA-1 study as well as the TASKi Phase 2 program.Based on the totality of the results of the OSKIRA Phase 3 program in patients with RA, AZ has decided that it will not proceed with regulatory filings and will return the rights to the compound to Rigel.

Fostamatini
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Rigels R348 to Initiate Phase 2 Clinical Trial in Dry Eye
2. Rigel Announces First Quarter 2013 Financial Results
3. Rigel Announces Fourth Quarter and Year End 2012 Financial Results
4. Rigel Announces Participation at Two Investor Conferences
5. Rigel to Present at BIO CEO & Investor Conference
6. Rigel to Present at Jefferies 2012 Global Healthcare Conference in London
7. Rigel Announces Third Quarter 2012 Financial Results
8. Rigel to Present at UBS Global Life Sciences Conference
9. Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for Discoid Lupus
10. Rigel Announces Second Quarter 2012 Financial Results
11. Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 Intarcia Therapeutics, Inc. today ... its lead candidate ITCA 650 (continuous subcutaneous delivery of ... HbA1c levels at the 50 th Annual Meeting ... (EASD). Data from the open-label, phase 3 FREEDOM-HBL (high ... in patients with poorly controlled type 2 diabetes. The ...
(Date:9/19/2014)... , September 19, 2014 Reductions ... for many years in people with diabetes type 2 ... long term benefits for the kidneys." Australian ... with type 2 diabetes leads to persistent reductions in ... The global study has found that, five ...
(Date:9/18/2014)... 18, 2014  Low T Center endorses the ... Hyattsville, Maryland earlier this ... proper patient population for testosterone therapy (TRT), as ... with TRT. Examining recent claims from studies that TRT ... epidemiological studies do not provide convincing evidence that ...
Breaking Medicine Technology:Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 3Low T Center Endorses The Joint FDA Committee Meeting on Testosterone 2
... LEWISBERRY, Pa. , Feb. 16 Unilife Corporation ... stock began trading on the NASDAQ Global Market on Tuesday, ... "This is a major step for Unilife Corporation, signifying the completion ... listed U.S. company.  I believe moving the Company to the U.S. ...
... , MALVERN, Pa. , Feb. 16 ... in a series of free Virtual Healthcare IT Conferences. The conference, accessed ... insights on achieving Meaningful Use of electronic health ... American Recovery & Reinvestment Act (ARRA), and how health IT technology can ...
Cached Medicine Technology:Unilife Corporation Commences Trading on the NASDAQ Global Market Under the Ticker Symbol 'UNIS' 2Unilife Corporation Commences Trading on the NASDAQ Global Market Under the Ticker Symbol 'UNIS' 3Siemens Hosts First In a Series of Free Virtual Healthcare IT Conferences 2Siemens Hosts First In a Series of Free Virtual Healthcare IT Conferences 3
(Date:9/19/2014)... (PRWEB) September 19, 2014 Boston Scientific ... mesh lawsuit ( http://www.transvaginalmeshlawsuithelp.com/ ) that is scheduled ... month, Bernstein Liebhard LLP reports. According to ... Court, the company asserts that claims involving its Solyx ... Practice and Remedies Code, a section of which shields ...
(Date:9/19/2014)... 19, 2014 (HealthDay News) -- Pregnant women who live in ... low birth weight babies, a new study suggests. Researchers ... and found that expectant mothers who lived in a neighborhood ... 20 percent lower risk of very preterm birth (before 30 ... birth (30 to 36 weeks). Babies born to mothers ...
(Date:9/19/2014)... HealthDay Reporter THURSDAY, ... by stress and family conflicts before surgery may face ... new study suggests. Investigators found that patients with ... three times greater risk for complications compared to those ... "We,ve long known that patient quality of life is ...
(Date:9/19/2014)... 2014 MetroMD, a leading anti-ageing clinic has ... of human health. This therapy has grown tremendously across USA ... more effective, safe and dependable. It has far reaching benefits ... to live a very healthy and active lifestyle even beyond ... therapy, a senior therapist at MetroMD said, “HGH or Human ...
(Date:9/19/2014)... 19, 2014 In partnership with Raw Beauty ... active part of the project’s social media efforts. StudioPMG is ... to re-define the perception of beauty as it applies to ... an idea by Shelly Baer and Vanessa Silberman, who wanted ... sexy and beautiful. Ginny Dixon, Wendy Crawford, Susan Solman and ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 4Health News:Do Greener Neighborhoods Produce Healthier Babies? 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 3Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2Health News:OC Healthcare Agency StudioPMG Partners with The Raw Beauty Project ™ NYC 2014 2
... (MRSA) and other pesky bacteria. Andrei Osterman ... identify new targets for antibiotics and produced first-generation chemical ... (nicotinate mononucleotide adenylyltransferases). Described in a recent article in ... led by Dr. Osterman, has provided proof of concept ...
... that may explain why the disease hasn,t posed more problems, study ... virus that,s sweeping across the United States isn,t a total stranger ... that should ease the most drastic worries about the lethality of ... press is that the swine flu is totally new, so there ...
... WYCKOFF, N.J., Nov. 16 HealthBarn USA®, ... for children and families, presented at the national Farm-Based ... in Tarrytown, NY held November 12-14, 2009. HealthBarn ... because of its focus on food and nutrition and ...
... , ATLANTA, Nov. 16 AutoTrader.com will use the power ... visitors, to help raise funds for St. Jude Children,s Research ... display ads throughout the site illustrating the research and treatment ... Also, individuals who purchase an advertisement to sell a vehicle ...
... Ga. A powerful new breast cancer treatment could ... inhibits cancer,s hallmark wild growth with another that blocks ... eats part of itself, researchers say. While they ... drugs called histone deacetylase inhibitors, or HDAC inhibitors, also ...
... Va. (Nov. 16, 2009) Virginia Commonwealth University Medical ... and survival rates dramatically for cardiac arrest patients by ... body temperature in the field during resuscitation and following ... strategies to improve the odds of survival. The ...
Cached Medicine News:Health News:The Burnham buzz 2Health News:The Burnham buzz 3Health News:The Burnham buzz 4Health News:Immunity to Swine Flu May Be Broader Than Thought 2Health News:Immunity to Swine Flu May Be Broader Than Thought 3Health News:Youth Nutrition Education Needed In Farm-Based Education Programs To Combat Childhood Obesity 2Health News:AutoTrader.com to Raise Money for St. Jude Children's Research Hospital(R) 2Health News:AutoTrader.com to Raise Money for St. Jude Children's Research Hospital(R) 3Health News:New combination therapy could deliver powerful punch to breast cancer 2Health News:Resuscitation and survival rates from out-of-hospital cardiac arrest nearly double 2Health News:Resuscitation and survival rates from out-of-hospital cardiac arrest nearly double 3Health News:Resuscitation and survival rates from out-of-hospital cardiac arrest nearly double 4Health News:Resuscitation and survival rates from out-of-hospital cardiac arrest nearly double 5
... warfarin for use by healthcare professionals and ... easy-to-read back-lit display and an operator rechargeable ... the ability to auto-send results to a ... LIS or EMR database through a clinical ...
... The NOW RSV test is the easiest ... are available in 15 minutes with no hands-on ... parents prior to the child leaving the pediatrician's ... hospital admission to help control outbreaks. Now the ...
The INRatio meter is a diagnostic Point Of Care system that provides Prothrombin Time (PT) and International Normalized Ratio (INR) results using one drop of fresh capillary whole blood from a finger...
... The Instacup Multi-Drug Screen Panel is used for the ... urine. The Instacup Panel consists of a test cup ... test card is inserted and the sample sealed with ... is not necessary to remove the test card to ...
Medicine Products: